124P Risk stratification in HR+/HER2- EBC: A comparative study of Prosigna and Oncotype DX with emphasis on menopausal status and lymph node involvement
Giulia Cursano(European Institute of Oncology), Nicola Fusco(European Institute of Oncology), Eltjona Mane(European Institute of Oncology), Elisabetta Munzone(Istituti di Ricovero e Cura a Carattere Scientifico), Elisa De Camilli(European Institute of Oncology), Mariia Ivanova(European Institute of Oncology), Silvia Dellapasqua(Istituti di Ricovero e Cura a Carattere Scientifico), G. Curigliano(European Institute of Oncology), Francesco Conversano(University of Parma), C. Criscitiello(European Institute of Oncology), Chiara Frascarelli(University of Milan), Giuseppe Viale(University of Milan), Antonio Marra(Memorial Sloan Kettering Cancer Center), Konstantinos Venetis(European Institute of Oncology), Giovanni Mazzarol(European Institute of Oncology), Oriana Pala(European Institute of Oncology)
Cited by 0
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)
|Archives of Pathology & Laboratory Medicine|2010|1.1k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Archives of Pathology & Laboratory Medicine|2010|898
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801